Connect to other sites within the UBM Medica Network
Majority of Metaplastic Breast Cancers May Be Targetable
In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
High Cost, Minimal Benefit for Bevacizumab in Metastatic CRC
Bevacizumab as first-line therapy for metastatic CRC equated to an incremental cost-effectiveness ratio of more than half a million dollars per QALY.
Physician Age May Affect Beliefs About Breast Cancer Screening
A physician’s age may have an effect on his or her opinions about the effectiveness of breast cancer screening methods, including self-exam and mammography.
HR-Positive Breast Cancer Patients May Have More Anxiety
Women with hormone receptor-positive breast cancer may be more scared, anxious, or concerned about treatment-related adverse events and cancer symptoms.
Enough is Enough: Screening Mammography Saves Lives
At MBCC, one presenter made the argument for screening mammography for all women starting at the age of 40, despite the controversy surrounding the topic.
Top 6 Highlights From the 2015 ASCO GU Cancers Symposium
This slide show includes some of the top highlights from the 2015 ASCO Genitourinary Cancers Symposium, including a study that examined the risk of aggressive prostate cancer in testicular cancer survivors and more.
Modern Breast Cancer Staging Should Include Tumor Biology
According to a presentation at MBCC, modern breast cancer staging systems should include grade, estrogen receptor status, and possibly other biologic markers.
Surveillance Risky in Intermediate-Risk Prostate Cancer?
Intermediate-risk prostate cancer patients managed with surveillance had worse outcomes compared with low-risk prostate cancer patients managed with surveillance.
High-Dose Radiotherapy Fails to Improve Prostate Cancer Survival
High-dose radiation therapy did not improve overall survival compared with the standard dose in stage II localized prostate cancer, but did show some benefits.
Eribulin Dose-Modification May Allow for Better Outcomes
Women with breast cancer who received first-line eribulin were able to stay on treatment longer and had better outcomes when they received dose modifications.
By clicking Accept, you agree to become a member of the UBM Medica Community.